2025
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates
Jansen C, Pagadala M, Cardenas M, Prabhu R, Goyal S, Zhou C, Chappa P, Vo B, Ye C, Hopkins B, Zhong J, Klie A, Daniels T, Admassu M, Green I, Pfister N, Neill S, Switchenko J, Prokhnevska N, Hoang K, Torres M, Logan S, Olson J, Nduom E, del Balzo L, Patel K, Burri S, Asher A, Wilkinson S, Lake R, Kesarwala A, Higgins K, Patel P, Dhere V, Sowalsky A, Carter H, Khan M, Kissick H, Buchwald Z. Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates. Nature Communications 2024, 15: 8854. PMID: 39402027, PMCID: PMC11473782, DOI: 10.1038/s41467-024-53034-6.Peer-Reviewed Original ResearchConceptsPre-operative stereotactic radiosurgeryCD8 T cellsEffector-like cellsT cellsStereotactic radiosurgeryBrain metastasesCD8 T cell responsesEndpoint of overall survivalDistant brain failureResected brain metastasesEfficacy of immunotherapyT cell responsesAntigen presenting cellsSecondary clinical endpointsLocal recurrenceLeptomeningeal diseaseOverall survivalImmune compositionProspective trialsImmune nichePrimary endpointImmunological correlatesPresenting cellsClinical outcomesPilot studyAmerican Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer
Rodrigues G, Higgins K, Rimner A, Amini A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Iyengar P, Movsas B, Ning M, Park H, Wolf A, Simone C. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology 2024, 10: 799-806. PMID: 38602670, PMCID: PMC11665040, DOI: 10.1001/jamaoncol.2024.0294.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAmerican Radium Society Appropriate Use CriteriaAdvanced non-small cell lung cancerAmerican Radium SocietyAppropriate Use CriteriaNon-small cell lung cancerLA-NSCLCUnresectable LA-NSCLCCell lung cancerTreatment of locally advanced non-small cell lung cancerUnresectable locally advanced non-small cell lung cancerLung cancerIntensity-modulated radiotherapy techniqueDecades of clinical trialsPlatinum-based chemoradiationLung cancer radiotherapyEvidence-based consensus documentMultidisciplinary patient careEvidence-based guidelinesRadiotherapy techniquesSalvage therapyFractionation schedulesLocal recurrenceSystemic therapyCancer radiotherapyMultimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence.
Thai J, Sodagari F, Colwell A, Winograd J, Revzin M, Mahmoud H, Mozayan S, Chou S, Destounis S, Butler R. Multimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence. RadioGraphics 2024, 44: e230070. PMID: 38573814, DOI: 10.1148/rg.230070.Peer-Reviewed Original ResearchConceptsTumor recurrencePostoperative evaluation of patientsFlap reconstruction methodsImplant-based reconstructionMultimodal imagingBreast reconstruction techniquesFat graft placementBreast cancer recurrenceTissue flap reconstructionEvaluation of patientsNipple-sparing techniquesTissue donor sitesFlap-based reconstructionNipple-areolar complex reconstructionDiagnostic breast imagingUnique patient populationAutologous tissue flapsAbnormal imaging appearancesBreast cancer screeningMastectomy optionLocal recurrenceOncoplastic surgeryDisease recurrenceFlap reconstructionReconstructed breast
2023
Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
Peters G, Cheng W, Boateng K, Knowlton C, Campbell A, Hayman T, Park H. Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e46-e47. DOI: 10.1016/j.ijrobp.2023.06.750.Peer-Reviewed Original ResearchStereotactic body radiation therapyPhase Ib/II trialCentral lung tumorsCancer-specific survivalProgression-free survivalLocal recurrenceLung tumorsInterim analysisII trialAdverse eventsOverall survivalDistant controlLocal controlGrade 2 adverse eventsUltra-central lung tumorsRisk dose constraintsRate of gradeSecondary lung tumorsCo-primary endpointsHigh toxicity ratesBiologically equivalent doseBody radiation therapyMATERIAL/METHODSRTOG 0236RTOG 0813
2022
Microsecretory adenocarcinoma: Cutaneous counterpart of a newly described salivary gland tumor with recurrent MEF2C::SS18 fusion
Panse G. Microsecretory adenocarcinoma: Cutaneous counterpart of a newly described salivary gland tumor with recurrent MEF2C::SS18 fusion. Journal Of Cutaneous Pathology 2022, 50: 188-190. PMID: 36308392, DOI: 10.1111/cup.14349.Commentaries, Editorials and LettersConceptsMicrosecretory adenocarcinomaSalivary gland tumorsGland tumorsLow-grade salivary gland tumorsHigh-grade featuresComplete surgical excisionUnique immunohistochemical profileMicrocystic tubulesCutaneous counterpartFibromyxoid stromaLocal recurrenceSurgical excisionHistopathological featuresIndolent tumorsImmunohistochemical profileClear cytoplasmUnique tumorOral cavityLuminal secretionsAccurate diagnosisTumorsSkinMolecular studiesVast majorityAdenocarcinomaRadiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatientsCirculating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, Krop IE, Knape C, Feger U, Marsico G, Howarth K, Winer EP, Lin NU, Parsons HA. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal Of Clinical Oncology 2022, 40: 2408-2419. PMID: 35658506, PMCID: PMC9467679, DOI: 10.1200/jco.22.00908.Peer-Reviewed Original ResearchConceptsMinimal residual diseaseWhole-exome sequencingClinical recurrenceMetastatic recurrenceBreast cancerEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerTumor tissueHigh-risk stage IIReceptor-positive breast cancerTumor DNAHuman epidermal growth factor receptorDistant metastatic recurrenceHormone receptor positiveMRD-positive patientsPlasma samplesTime of consentPrimary tumor tissuesSufficient tumor tissueEpidermal growth factor receptorAdjuvant settingGrowth factor receptorLocal recurrenceClinical outcomesDistant metastasisLocal recurrence of uveal melanoma and concomitant brain metastases associated with an activating telomerase promoter mutation seven years after secondary enucleation
Heng JS, Perzia BM, Sinard JH, Pointdujour-Lim R. Local recurrence of uveal melanoma and concomitant brain metastases associated with an activating telomerase promoter mutation seven years after secondary enucleation. American Journal Of Ophthalmology Case Reports 2022, 27: 101607. PMID: 35707052, PMCID: PMC9189986, DOI: 10.1016/j.ajoc.2022.101607.Peer-Reviewed Original ResearchConcomitant brain metastasesOptic nerve massRecurrent uveal melanomaLocal recurrenceSecondary enucleationUveal melanomaBrain metastasesSystemic metastasesNerve massMultiple mass lesionsOptic nerve invasionYear old patientNext-generation sequencingSeven yearsNerve invasionExtrascleral extensionGait instabilityMass lesionPrimary tumorPatient historyAnophthalmic socketHigh riskRecurrenceEnucleationMetastasis
2021
Sinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm.
Al-Jobory YM, Pan Z, Manes RP, Omay SB, Ikuta I. Sinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm. The Yale Journal Of Biology And Medicine 2021, 94: 593-597. PMID: 34970096, PMCID: PMC8686777.Peer-Reviewed Original ResearchConceptsWorld Health OrganizationParanasal sinusesNasal cavityClinical management updateRare sinonasal neoplasmSlight female predominanceLow malignant potentialComplete surgical excisionNon-specific appearanceCase of glomangiopericytomaDecade of ageAggressive treatmentExcellent prognosisSinus massFemale predominanceLocal excisionLocal recurrenceMale patientsSurgical excisionRare tumorMalignant potentialImaging appearancesSinonasal neoplasmsSinonasal cavityTumor extentLocal Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer
Bellon J, Tayob N, Burstein H, Partridge A, Demeo M, Tralins J, Yang D, Dang C, Isakoff S, Yardley D, Valero V, Winer E, Krop I, Tolaney S. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s34. DOI: 10.1016/j.ijrobp.2021.07.103.Peer-Reviewed Original ResearchT-DM1 armBreast conserving surgeryPartial breast irradiationT-DM1Radiation therapyBreast cancerLocal recurrenceSkin toxicityGrade 2 acute skin toxicityProspective randomized phase II studyGrade 3 skin toxicityHormone receptor-positive diseaseRandomized phase II studyPhase II Randomized TrialAdjuvant T-DM1Conclusions Radiation therapyGrade 2 pneumonitisGrade 3 pneumonitisIpsilateral rib fracturesPhase II studyReceptor-positive diseaseWeeks of therapyAcute skin toxicityAnti-HER2 therapyNodal radiation therapySBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer
Morris L, Viehman J, Baclay J, Chang D, Kerans S, Molitoris J, Regine W, Johung K, Jethwa K, Neibart S, Jabbour S, Hallemeier C. SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e61. DOI: 10.1016/j.ijrobp.2021.07.408.Peer-Reviewed Original ResearchStereotactic body radiation therapyPancreatic ductal adenocarcinomaSurgical resectionFirst recurrenceCumulative incidenceLocal recurrenceDistant metastasisCompletion of SBRTTime of SBRTLow treatment-related toxicityMulti-institutional retrospective analysisDetails of recurrenceGrade 3 toxicityPrior treatment characteristicsInitial surgical resectionR0 resection rateTreatment-related toxicityRisk of progressionIsolated local recurrenceOverall survival estimatesLocal tumor controlSuperior mesenteric arteryBody radiation therapyKaplan-Meier modelOncologic surgical resectionUtility of expanded anterior column resection versus decompression-alone for local control in the management of carcinomatous vertebral column metastases undergoing adjuvant stereotactic radiotherapy
Pennington Z, Pairojboriboon S, Chen X, Sacino A, Elsamadicy AA, de la Garza Ramos R, Patel J, Elder BD, Kleinberg LR, Sciubba DM, Redmond KJ, Lo SL. Utility of expanded anterior column resection versus decompression-alone for local control in the management of carcinomatous vertebral column metastases undergoing adjuvant stereotactic radiotherapy. The Spine Journal 2021, 22: 835-846. PMID: 34718175, DOI: 10.1016/j.spinee.2021.10.016.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyLong-term local controlLocal recurrenceLocal controlAnterior columnTumor pathologyCommon primary tumor typesSingle comprehensive cancer centerAdjuvant stereotactic radiotherapySpinal column metastasesVertebral Column MetastasesRetrospective cohort studyLocal control ratePrimary tumor typeLocal tumor recurrenceComprehensive cancer centerKaplan-Meier functionInvasive surgical techniquesEpidural removalAdjuvant radiotherapySurgical debulkingCohort studyDisease resectionSpinal metastasesTumor involvementDrivers of Readmission and Reoperation After Surgery for Vertebral Column Metastases
Patel J, Pennington Z, Hersh AM, Hung B, Schilling A, Antar A, Elsamadicy AA, de la Garza Ramos R, Lubelski D, Larry Lo SF, Sciubba DM. Drivers of Readmission and Reoperation After Surgery for Vertebral Column Metastases. World Neurosurgery 2021, 154: e806-e814. PMID: 34389529, DOI: 10.1016/j.wneu.2021.08.015.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexSpinal metastasis surgeryComprehensive cancer centerUnplanned reoperationMedical comorbiditiesMetastasis surgeryIndependent predictorsUnplanned readmissionWound infectionCancer CenterDrivers of readmissionsLonger index admissionsVertebral Column MetastasesBaseline laboratory valuesMultivariable logistic regressionLength of stayPopulation of adultsOutcomes of interestWound healing factorsComorbidity indexIndex admissionVenous thromboembolismLocal recurrenceSurgical morbidityMultivariable analysisCost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
Mojtahed S, Boyer N, Rao S, Gajewski T, Tseng J, Turaga K. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Annals Of Surgical Oncology 2021, 28: 9039-9047. PMID: 34129153, DOI: 10.1245/s10434-021-10288-4.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsDabrafenib-trametinibAdjuvant therapyNo treatmentFirst-line targeted therapyInclusion of adjuvant therapyCost-effectiveness analysisAcceptable WTP thresholdStage III melanomaRecurrence-free survivalPublished clinical trialsDrug price databaseIncremental quality-adjusted life-yearsLife yearsMarkov microsimulation modelCost-effectiveness ratioProbabilistic sensitivity analysesMedicare patient populationBackgroundAdjuvant therapyIII melanomaLocal recurrenceResected stageEffective immunotherapyDistant metastasisA prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseasePhase 2/3 studyCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewLesion countsA Histopathologic Scoring System for Perineural Invasion Correlates With Adverse Outcomes in Patients With Cutaneous Squamous Cell Carcinoma.
Totonchy MB, McNiff JM, Suozzi KC, Leffell DJ, Christensen SR. A Histopathologic Scoring System for Perineural Invasion Correlates With Adverse Outcomes in Patients With Cutaneous Squamous Cell Carcinoma. Dermatologic Surgery 2021, 47: 445-451. PMID: 33795563, DOI: 10.1097/dss.0000000000002923.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaPerineural invasionSquamous cell carcinomaAdverse outcomesNerve diameterHistopathologic featuresPNI scoreCell carcinomaExtratumoral perineural invasionRetrospective cohort studyCurrent staging systemHistopathologic scoring systemTumor-related deathNumber of nervesLogistic regression analysisMedian followNerve involvementCohort studyLocal recurrenceSurgical excisionStaging systemRisk factorsMedian numberHistopathologic slidesNerve structuresA prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyPhase II/III studyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseaseCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceIII studyStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging review
2020
Laser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases
Sujijantarat N, Hong CS, Owusu KA, Elsamadicy AA, Antonios JP, Koo AB, Baehring JM, Chiang VL. Laser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases. Journal Of Neuro-Oncology 2020, 148: 641-649. PMID: 32602021, DOI: 10.1007/s11060-020-03570-0.Peer-Reviewed Original ResearchConceptsLaser interstitial thermal therapyLonger overall survivalRadiation necrosisInterstitial thermal therapyBrain metastasesOverall survivalMedian volume decreaseMedian volume increaseBrain metastasis patientsPre-treatment patient characteristicsRetrospective chart reviewResultsTwenty-five patientsPre-treatment factorsBevacizumab patientsChart reviewMetastasis patientsLocal recurrencePatient characteristicsTreatment optionsTreatment responseBevacizumabPatientsLesional volumeThermal therapyStatistical significanceAdherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. DOI: 10.1200/jco.2020.38.15_suppl.527.Peer-Reviewed Original ResearchLate distant recurrenceAdjuvant endocrine therapyEndocrine therapyDistant recurrenceDXA scansBreast cancerHigh riskStage IEarly-stage hormone receptorExtended endocrine therapyIntolerable side effectsOsteopenia/osteoporosisPositive breast cancerRate of adherenceSerious adverse effectsBreast cancer recurrenceMajority of ptsHigher likelihoodElectronic health recordsLocal recurrenceMedian ageLate recurrenceMetastatic recurrenceTumor characteristicsMedication adherence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply